Sep 25
Healthcare holds up to 5 names from healthcare stocks above $200M. Selection follows the model's positive score together with its composite positive factor.
Equal capital goes into every recommendation. Recommendations are published a few hours before the open and placed as market orders, so buys and sells fill at the opening price. Positions are held for 6 to 21 days. Every position carries a 20% stop-loss: if the price touches it during the day, the position is sold there, at 80% of its entry price. Reported returns are measured from those opening prices and include every stop-loss exit.
The Centers for Medicare & Medicaid Services (CMS) has granted a New Technology Add-on Payment (NTAP) of up to $2,171 per eligible Medicare inpatient case for the Ceribell Delirium Monitor System. This reimbursement, effective October 1, 2026, is expected to drive adoption and revenue growth for the company's delirium monitoring solution.
StockTitanJade Biosciences management presented its clinical strategy and pipeline updates at the Stifel Virtual Immunology and Inflammation Forum. While the presentation highlighted progress for lead candidate JADE101, the stock declined following the event, reflecting broader market sentiment and investor digestion of the company's long-term clinical roadmap.
Investing.comFollowing investor meetings with management, BTIG reiterated a Buy rating and $30 price target for CBLL. The firm highlighted confidence in the company's growth drivers, including the Veterans Affairs expansion and the upcoming delirium launch, as well as a strong gross margin profile.
Investing.comDirector Thomas Stephen Basil sold 100,000 shares of common stock on September 15, 2026, under a pre-arranged Rule 10b5-1 trading plan adopted in June 2026. While such sales are routine and planned, they can occasionally trigger short-term negative sentiment regarding insider confidence.
SEC Filing (Form 4)The company participated in the H.C. Wainwright Global Investment Conference on September 15, 2026. As this event has already occurred, it is no longer a forward-looking catalyst.
GlobeNewswireMultiple executives, including the CEO and CFO, reported selling shares of common stock in mid-September 2026. These transactions were executed pursuant to pre-arranged Rule 10b5-1 trading plans, which are typically used to sell shares systematically rather than based on non-public information.
StockTitanThe company participated in the Cantor Global Healthcare Conference on September 9, 2026. As this event has already occurred, it is no longer a forward-looking catalyst.
GlobeNewswireClimb Bio announced positive Phase 1 results for CLYM116, an anti-APRIL monoclonal antibody for IgA nephropathy, demonstrating a prolonged half-life and potential for every-12-week dosing. This event serves as a fundamental catalyst, though its immediate market impact has been partially absorbed by the stock's recent price action.
SEC Filing (Form 8-K)